All In Biotech

Free tool

FAERS Monitor: Ninlaro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208462 or its brand name (Ninlaro, Ixazomib Citrate). Reports on generic versions are filed under their own applications.

Reports

28,726

Serious

21,353

74% of reports

Hospitalization

8,767

Death reported

5,294

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • plasma cell myeloma3,689
  • death3,317
  • diarrhoea3,163
  • off label use2,976
  • pneumonia1,937
  • fatigue1,921
  • nausea1,847
  • neuropathy peripheral1,454
  • vomiting1,110
  • rash1,089
  • thrombocytopenia1,050
  • platelet count decreased1,008
  • constipation968
  • asthenia917
  • product dose omission issue802

Reports by year received

View as table
YearReports
20131
20143
201563
20161,879
20172,393
20183,382
20194,438
20204,066
20214,533
20222,966
20231,976
20241,630
20251,042
2026354

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,433 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
plasma cell myelomaSignal3,68976.374.0248,797
neuropathy peripheralSignal1,45411.310.813,564
platelet count decreasedSignal1,0087.06.65,137
thrombocytopeniaSignal1,0506.96.55,301
pneumoniaSignal1,9374.44.25,136
diarrhoeaSignal3,1633.63.56,096
constipationSignal9683.33.11,523
deathSignal3,3172.82.74,063
off label useSignal2,9762.52.42,767
product dose omission issue8022.01.9404
rash1,0891.81.7418
fatigue1,9211.81.7719
asthenia9171.81.7322
vomiting1,1101.71.6348
nausea1,8471.71.6564

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.